These 123 cases were categorized further based on receptor expression as Luminal A (n = 60), Luminal B (n = 9), HER2+ (n = 12), and triple-negative breast cancer (TNBC) (n = 42). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.